Oxytocin
Pitocin · Endogenous nonapeptide
An endogenous hormone and approved medication in specific obstetric settings, with additional CNS research.
Mechanism
Oxytocin receptor agonist
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Obstetric patients under medical supervision
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common intranasal research range | 10–40 IU | 10–40 IU per administration | As needed | 30–60 minutes before the research window | Intranasal | Community-reported |
| Low subcutaneous community range | 100 mcg (~50 IU) | 100 mcg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
| Moderate subcutaneous community range | 200–300 mcg (~100–150 IU) | 200–300 mcg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
| Upper subcutaneous community range | 400–500 mcg (~200–250 IU) | 400–500 mcg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Rounded calculation: concentration is about 1.67 mg/mL, so 200 mcg equals about 0.12 mL (12 U-100 units). The approximate oxytocin-specific conversion is 1 IU ≈ 2 mcg; subcutaneous use is investigational.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 100 mcg (~50 IU) | Once daily | 0.7 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 4 weeks | 2.8 mg | 1 × 5 mg | 50 administrations |
| 8 weeks | 5.6 mg | 2 × 5 mg | 50 administrations |
| 12 weeks | 8.4 mg | 2 × 5 mg | 50 administrations |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 4 weeks | 3 mL | 1 × 10 mL |
| 8 weeks | 6 mL | 1 × 10 mL |
| 12 weeks | 6 mL | 1 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 4 weeks | 28 | 28 |
| 8 weeks | 56 | 56 |
| 12 weeks | 84 | 84 |
Ranges reflect the low and high ends of the displayed community schedule. Vials and 10 mL water bottles are rounded up; one new U-100 syringe is counted per subcutaneous administration.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Administration can cause serious uterine, cardiovascular and fluid-balance complications; CNS claims require separate evidence.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.